Vor Biopharma
71 hedge funds and large institutions have $54.5M invested in Vor Biopharma in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 20 closing their positions.
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
4% more funds holding
Funds holding: 68 → 71 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.33% less ownership
Funds ownership: 4.32% → 3.99% (-0.33%)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
61% less capital invested
Capital invested by funds: $140M → $54.5M (-$85.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$456K |
| 2 |
Millennium Management
New York
|
+$374K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$357K |
| 4 |
Jane Street
New York
|
+$328K |
| 5 |
Renaissance Technologies
New York
|
+$260K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.83M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$2.63M |
| 3 |
AG
Artal Group
Luxembourg
|
-$2.37M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.06M |
| 5 |
State Street
Boston,
Massachusetts
|
-$876K |
VOR Hedge Fund Activity: Q2 2024 in Review
71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2024, worth a combined $54.5M — down 61% from $140M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VOR positions and 20 closed out — a net gain of 3 holders — while 17 added to existing stakes and 19 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $456K. The largest seller was BlackRock, cutting an estimated $2.83M.
- 71 institutional investors held Vor Biopharma (VOR) as of Q2 2024, up from 68 in Q1 2024.
- Funds reported $54.5M of Vor Biopharma stock for Q2 2024, down 61% quarter-over-quarter.
- 23 funds opened new Vor Biopharma positions in Q2 2024 and 20 closed out, a net change of +3 holders.
- The largest Vor Biopharma buyer in Q2 2024 was Goldman Sachs, an estimated $456K added.
- The largest Vor Biopharma seller in Q2 2024 was BlackRock, an estimated $2.83M sold.
Based on aggregated 13F filings for Q2 2024.